Tokushima University / Educator and Researcher Directory --- Maeda, Yusaku

Search:

Tokushima University ⟩ University Hospital ⟩ Central Clinical Facilities ⟩ Tokushima Community Medical Support Center ⟩
Tokushima University ⟩ University Hospital ⟩ Clinical Division ⟩ Department of Internal Medicine ⟩ Hematology ⟩

(Files for researchmap) [PDF manual] [Auto-propagate to researchmap]

Research

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

1.	Mizuki Yoshimoto, Shin-ichiro Yanagiya, Hiroki Takanari, Takeshi Honda, Yusaku Maeda, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Takeshi Harada, Shiro Fujii, Shingen Nakamura, Yoshimi Bando, Koichi Tsuneyama, Itsuro Endo, Masahiro Abe, Ken-ichi Matsuoka and Hirokazu Miki : Development of a rapid and novel diagnostic technique for cardiac amyloidosis using Raman spectroscopy., Research Square, 2025. (Summary) Although the prognosis of cardiac amyloidosis has improved with the development of therapies, the time required for disease typing remains a critical issue. We investigated the potential of Raman spectroscopy for the more rapid diagnosis and typing of cardiac amyloidosis. Heart biopsies were collected from patients with the AL (4) and ATTR (4) types of cardiac amyloidosis, and tissue sections were subjected to Raman microscopy. A principal component analysis (PCA) of spectral data was performed and receiver operating characteristic (ROC) curves were created to confirm the accuracy of discriminating between amyloid-deposition and non-deposition sites, and between AL and ATTR. The steep peak at 1680 cm-1, reflecting the β-sheet structure, was useful for detecting the amyloid-deposition region. By restricting the spectral analysis to amyloid-deposition sites, AL and ATTR were discriminated by principal components with a characteristic broad peak at 1520-1540 cm-1, which was also observed in the Raman spectrum of AL, but not ATTR. The area under ROC curve discriminating AL and ATTR was 0.78. PCA of the Raman spectra of cardiac biopsies has the potential not only to detect amyloid-deposition sites in tissue but also to rapidly discriminate between the AL and ATTR types of cardiac amyloidosis. (Link to Publication Site) ● Publication site (DOI): 10.21203/rs.3.rs-6795517/v1 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 40678255 ● Search Scopus @ Elsevier (PMID): 40678255 ● Search Scopus @ Elsevier (DOI): 10.21203/rs.3.rs-6795517/v1 (DOI: 10.21203/rs.3.rs-6795517/v1, PubMed: 40678255)
2.	Kazuko Akashi, Yoshie Imai, Shingen Nakamura, Yusaku Maeda, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Mamiko Takahashi, Shiroh Fujii, Takeshi Harada and Hirokazu Miki : Preparedness for the future in patients with relapsed or refractory hematopoietic malignancies in the treatment process: a qualitative study, Annals of Palliative Medicine, 14, 1, 43-56, 2025. (Summary) This study aims to clarify how patients with relapsed or refractory (R/R) hematological malignancies prepare for the future and set treatment goals. R/R hematological malignancies often require intensive therapies, including stem cell transplantation and CAR-T cell therapy, which pose high risks of adverse events. Many patients continue aggressive treatment until the end of life for pain relief or even a potential cure, despite the significant symptom burden. Understanding each patient's treatment motivations and preferences is essential to aligning care with their individual values. By examining their experiences, current health status, and treatment goals, this study seeks to provide a basis for holding early discussions on future care, contributing to individualized decision-making support for patients facing limited treatment options and uncertain prognoses. A qualitative descriptive study design was used to conduct semi-structured interviews with 16 patients with relapsed/refractory hematopoietic malignancies who were hospitalized for chemotherapy. The four main themes expressed by the participants were (I) I want to live through the treatment until the end of my life because I know recovery is difficult; (II) my current treatment depends on how much my body can endure; (III) I want to keep trying, but I am at the limit of what I can do now; and (IV) I want to continue even if the treatment is limited because I think it will help someone else. Patients with hematopoietic malignancies who are undergoing treatment may be motivated by a variety of different factors to continue with treatment. Discussing patients' goals and wishes with respect to treatment is critically important to ensure that such treatment is aligned with patients' preferences. (Keyword) Humans / Hematologic Neoplasms / Male / Female / Middle Aged / Qualitative Research / Adult / Aged / Palliative Care (Link to Publication Site) ● Publication site (DOI): 10.21037/apm-24-124 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 39963757 ● Search Scopus @ Elsevier (PMID): 39963757 ● Search Scopus @ Elsevier (DOI): 10.21037/apm-24-124 (DOI: 10.21037/apm-24-124, PubMed: 39963757)

Proceeding of Domestic Conference:

1.	Kimiko Sogabe, Shiroh Fujii, Masahiro Oura, Takeshi Harada, Hirokazu Miki, Yusaku Maeda, 八木ひかる (名), Ryohei Sumitani, Shingen Nakamura and Ken-ichi Matsuoka : Successful allo-HSCT in two patients with refractory hepatosplenic T-cell lymphoma (HSTL), 第47回日本造血・免疫細胞療法学会総会, Mar. 2025.
2.	Shiroh Fujii, Kimiko Sogabe, Yusaku Maeda, Ryohei Sumitani, 八木ひかる, Masahiro Oura, Takeshi Harada, Shingen Nakamura, Hirokazu Miki and Ken-ichi Matsuoka : 診断に苦慮したPh陽性B-ALL/LBLの1例, 第64回日本血液学会中国四国地方会, Mar. 2025.
3.	Masahiro Oura, Shingen Nakamura, Yusaku Maeda, Ryohei Sumitani, Kimiko Sogabe, 八木ひかる, Takeshi Harada, Shiroh Fujii, Hirokazu Miki, 河村若菜, 鎌田涼香, 樫地舞子, 三木こずえ, 小林誠司, 緒方良輔, 佐藤翔平, 市原知怜, 小松崇俊, 武田悠作, 近田優介, 斎藤貴, 古本みゆ, Takahisa Inoue and Ken-ichi Matsuoka : 外国人患者に対する造血幹細胞移植における「言語の壁」の克服, 第47回日本造血・免疫細胞療法学会総会, Mar. 2025.
4.	森本くるみ, 玉谷香住里, 山本英之, 新居清美, 三木こずえ, Yoshie Imai, Yusaku Maeda, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, 八木ひかる, Takeshi Harada, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki and Ken-ichi Matsuoka : 同種造血幹細胞移植を受けた壮年期患者の原動力, 第47回日本造血・免疫細胞療法学会総会, Mar. 2025.
5.	Shiroh Fujii, Kimiko Sogabe, 湯浅麻美, 西尾進, Yusaku Maeda, 八木ひかる, Ryohei Sumitani, Masahiro Oura, Takeshi Harada, Shingen Nakamura, Hirokazu Miki and Ken-ichi Matsuoka : 肝類洞閉塞症候群/肝中心静脈閉塞症の早期診断におけるHokUS-6の有用性の検討, 第47回日本造血・免疫細胞療法学会総会, Mar. 2025.
6.	Hiroyoshi Watanabe, Kazumi Okamura, Yusaku Maeda, Ryohei Sumitani, Masahiro Oura, Takeshi Harada, Shingen Nakamura, Hirokazu Miki and Maki Urushihara : ROTEMによるインヒビター陽性血友病A患者のヒトFX加VIIa製剤及びrVIIa併用時の血液凝固機能評価, 日本血液学会学術集会, 274, Oct. 2024.